Company intelligence / Profile preview

Natural Cycles

Ownership: Private
Employees: ~120
Development stage: Other

Overview

The NC° app has been clinically validated and cleared as a Class II medical device for contraception in the US and multiple other countries. It demonstrates 93% effectiveness with typical use and up to 98% with perfect use. Over four million users have registered globally; more than twenty peer-reviewed studies support its efficacy. The company continues to expand regulatory clearances and product integrations.

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy (fertility awareness-based method)
Industry: Digital Health Medical Devices

Partnerships

Clearblue®/Swiss Precision Diagnostics partnership for combined digital ovulation test + app kit

Beyond the preview

Go deeper on Natural Cycles.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural Cycles.

Explore the full profile